Management of attention deficit hyperactivity disorder

Psychosocial

There are a variety of psychotherapeutic approaches employed by psychologists and psychiatrists; the one used depends on the patient and the patient's symptoms. The approaches include psychotherapy, cognitive-behavior therapy, support groups, school-based interventions, parent training, meditation, mindfulness, neurofeedback, and social skills training. In a 2019 review the effectiveness of social skills training was evaluated in children aged 5 to 18 years. At the time there was little evidence to support or refute this type of training for the treatment of ADHD in this age group.

Parents and classroom

Improving the surrounding home and school environment can improve the behavior of children with ADHD. Parents of children with ADHD often show similar deficits themselves, and thus may not be able to sufficiently help the child with his or her difficulties. Improving the parents' understanding of the child's behavior and teaching them strategies to improve functioning and communication and discourage unwanted behavior has measurable effect on the children with ADHD. The different educational interventions for the parents are jointly called Parent Management Training. Techniques include operant conditioning: a consistent application of rewards for meeting goals and good behavior (positive reinforcement) and punishments such as time-outs or revocation of privileges for failing to meet goals or poor behavior.. Classroom management is similar to parent management training; educators learn about ADHD and techniques to improve behavior applied to a classroom setting. Strategies utilized include increased structuring of classroom activities, daily feedback, and token economy.

Cognitive training

Cognitive trainings can be delivered in a number of methods, including at home or hospital based programs. A 2013 paper published by two researchers from the University of Oslo concluded that working memory training provides short term improvements, but that there was limited evidence that these improvements were sustained or that they were generalized to improved verbal ability, mathematical skills, attention, or word decoding. A 2014 paper published by a group of researchers from the University of Southampton presented the result of meta analysis study of 14 recently published randomized controlled trials (RCTs). The authors concluded that "more evidence from well-blinded studies is required before cognitive training can be supported as a frontline treatment of core ADHD symptoms". A more recent 2023 meta-analysis of RCTs examined the efficacy of computerized cognitive training (CCT) in reducing ADHD symptoms through computer programs. In addition to finding short-term working memory improvements, they also found some evidence of long-term verbal working memory effects. However, the results were limited to the study's settings, and the authors highlighted the need for more targeted intervention strategies.

Medications

Stimulants ===

Stimulants are the most commonly prescribed medications for ADHD. The stimulant medications indicated to treat ADHD are methylphenidate (Ritalin, Biphentin, Concerta), dexmethylphenidate (Focalin, Focalin XR), Serdexmethylphenidate/dexmethylphenidate (Azstarys), mixed amphetamine salts (Adderall, Mydayis), dextroamphetamine (Dexedrine), lisdexamfetamine (Vyvanse), and in rare cases dextromethamphetamine (Desoxyn). Controlled-release pharmaceuticals may allow once daily administration of medication in the morning. This is especially helpful for children who do not like taking their medication in the middle of the school day. Several controlled-release methods are used.

Stimulants used to treat ADHD raise the extracellular concentrations of the neurotransmitters dopamine and norepinephrine, which increases cellular communication between neurons that utilize these compounds. Stimulants increase the availability of synaptic dopamine, reduce the overactivity, impulsivity, and inattention characteristics of patients with ADHD, and improve associated behaviors, including on-task behavior, academic performance, and social functioning.

The therapeutic benefits are due to noradrenergic effects at the locus coeruleus and the prefrontal cortex and dopaminergic effects at the ventral tegmental area, nucleus accumbens, and prefrontal cortex. This elevation of catecholamines, predominantly in the prefrontal cortex, preferentially activates dopamine D1 and norepinephrine α2 receptors, both of which are crucial for mediating cognitive processes including attention, inhibitory control, and working memory. Neuroimaging studies have shown that stimulants act to modulate activity in the right inferior frontal cortex and insula—regions implicated in attention and inhibition—and regulate fronto-striato-parietal networks, which are often dysregulated in ADHD. These effects are manifested in correlated clinical improvements in attention, reduced distractibility, and decreased hyperactivity and impulsivity.

Stimulant medications are considered safe when used under medical supervision. Nonetheless, there are concerns that the long term safety of these drugs has not been adequately documented, as well as social and ethical issues regarding their use and dispensation. The U.S. FDA has added black-box warnings to some ADHD medications, warning that abuse can lead to psychotic episodes, psychological dependence, and that severe depression may occur during withdrawal from abusive use. Studies consistently show that most students report using stimulant medications, legally or illegally to improve academic performance, specifically to increase concentration, organization, and the ability to stay up longer and study. The abuse of this drug has made prescribing it much more meticulous.

Stimulants are some of the most effective medications available for the treatment of ADHD. Seven different formulations of stimulants have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD: four amphetamine-based formulations, two methylphenidate-based formulations, and dextromethamphetamine hydrochloride. Atomoxetine, viloxazine, guanfacine, and clonidine are the only non-controlled, non-stimulant FDA approved drugs for the treatment of ADHD.

Short-term clinical trials have shown medications to be effective for treating ADHD, but the trials usually use exclusion criteria, meaning knowledge of medications for ADHD is based on a small subset of the typical patients seen in clinical practice. They have not been found to improve school performance and data is lacking on long-term effectiveness and the severity of side effects. Stimulants, however, may reduce the risk of unintentional injuries in children with ADHD.

This class of medicines is generally regarded as one unit; however, they affect the brain differently. Some investigations are dedicated to finding the similarities of children who respond to a specific medicine. The behavioral response to stimulants in children is similar regardless of whether they have ADHD or not.

Stimulant medication is an effective treatment for adult attention-deficit hyperactivity disorder although the response rate may be lower for adults than children. A 2025 meta-analytic systematic review of 113 randomized controlled trials demonstrated that stimulant medications significantly improved core ADHD symptoms in adults over a three-month period, with good acceptability compared to other pharmacological and non-pharmacological treatments. Some physicians may recommend antidepressant drugs as the first line treatment instead of stimulants although antidepressants have much lower treatment effect sizes than stimulant medication.

Amphetamine

Amphetamine is a chiral compound which is composed of two isomers: levoamphetamine and dextroamphetamine. Levoamphetamine and dextroamphetamine have the same chemical formula but are mirror images of each other, the same way that a person's hands are the same but are mirror images of each other. This mirror difference is enough to produce a small difference in their pharmacological properties; levoamphetamine has a slightly longer half-life and confers greater peripheral effects than dextroamphetamine, whereas dextroamphetamine is a more potent central nervous system stimulant. Although it is effective in reducing primary ADHD symptoms such as hyperactivity and inattention, multiple adverse side effects presented. Included in these were headaches, anxiety, nausea and insomnia.

Five different amphetamine-based pharmaceuticals are currently used in ADHD treatment: racemic amphetamine, dextroamphetamine, lisdexamfetamine, and two mixed enantiomer products (Adderall and Dyanavel XR). Lisdexamfetamine is an inactive prodrug of dextroamphetamine (i.e., lisdexamfetamine itself does not do anything in the body, but it metabolizes into dextroamphetamine). Adderall is a proprietary mixture of (75%) dextroamphetamine and (25%) levoamphetamine salts, which results in very mild differences between their effects. Dyanavel XR contains a similar mixture. Levoamphetamine-containing mixtures may result in longer clinical effects, relative to enatiopure dextroamphetamine, due to levoamphetamine's longer half-life. Some children with ADHD have been reported to respond better to medications containing levoamphetamine. Amphetamines are modestly more effective than methylphenidate but report more side effects.

Clinical research indicates that amphetamine's treatment efficacy for ADHD may vary depending on menstrual cycle phase, possibly due to fluctuations in female sex hormones. In menstruating individuals with ADHD, subjective and behavioral responses to amphetamine appear to be heightened during the follicular phase (i.e., when estrogen levels are higher), and reduced during the luteal phase (i.e., when progesterone is elevated); subjective responses to amphetamine appear to correlate positively with plasma or salivary estrogen concentrations. Some preliminary observational evidence suggests that treatment response to amphetamine may be improved in affected individuals when doses are adjusted according to menstrual cycle phases, but randomized controlled trials have not evaluated this practice.

Methamphetamine

Methamphetamine, prescribed as its dextrorotatory enantiomer dextromethamphetamine under the brand name Desoxyn, is a second-line psychostimulant for ADHD in the United States. Despite having a similar therapeutic mechanism of action as first-line medications containing amphetamine, the prescription of dextromethamphetamine for ADHD is rare due its relatively greater reinforcing potential, in addition to the comparable efficacy and presumably greater safety of methylphenidate and amphetamine. The body metabolizes methamphetamine into amphetamine (in addition to less active metabolites). A quarter of methamphetamine will ultimately become amphetamine. After comparing only the common ground between dextroamphetamine and dextromethamphetamine, the latter is said to be the stronger stimulant.

Methylphenidate

Like amphetamine, methylphenidate (MPH) is a chiral compound which is composed of two isomers: d-threo-methylphenidate (also known as dexmethylphenidate, d-methylphenidate, or d-MPH) and l-threo-methylphenidate (also known as l-methylphenidate or l-MPH). Both isomers have the same chemical formula but are mirror images of each other, the same way that a person's hands are the same but are mirror images of each other. Unlike amphetamine, the difference in pharmacological properties between d-MPH and l-MPH is significant, as l-MPH is markedly inferior to d-MPH in its effects, which is due to a number of major differences between the isomers.

The effectiveness of methylphenidate is comparable to atomoxetine but modestly lower than amphetamines.

There are two major medications derived from methylphenidate's isomers: a racemic mixture of half d-threo-methylphenidate and half l-threo-methylphenidate called methylphenidate (Ritalin, Concerta), and an enantiopure formulation containing just d-threo-methylphenidate called dexmethylphenidate (Focalin).

Non-stimulants

Atomoxetine, viloxazine, guanfacine, and clonidine are drugs approved for the treatment of ADHD that have been classified as "non-stimulant".

Based on a recent systematic literature review of diverse ADHD treatment modalities, no differences were found between stimulants and non-stimulants in their effectiveness in treating ADHD symptoms in children and adolescents.

; Atomoxetine : Atomoxetine is a selective norepinephrine reuptake inhibitor. It has comparable efficacy, tolerability and response rate to methylphenidate in children and adolescents; efficacy and discontinuation rate is equivalent in adults. It carries a U.S. FDA black box warning regarding suicidal ideation and is associated with rare cases of liver damage. Controlled studies show increases in heart rate, decreases of body weight, decreased appetite and treatment-emergent nausea. ; Viloxazine : Acts as a selective norepinephrine reuptake inhibitor (NRI). However, it may also act as an antagonist of the serotonin 5-HT2B receptor and as an agonist of the serotonin 5-HT2C receptors, actions which may be involved in its therapeutic effects. It was marketed for more than two decades as an antidepressant in Europe before being repurposed as a treatment for ADHD and launched in the United States in April 2021. ; Guanfacine : The extended release form has been approved by the FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in children as an alternative to stimulant medications. Its beneficial actions are likely due to its ability to strengthen prefrontal cortical regulation of attention and behavior. ; Clonidine : An α2A adrenergic receptor agonist has also been approved in the US. Clonidine was initially developed as a treatment for high blood pressure. Low doses in evenings and/or afternoons are sometimes used in conjunction with stimulants to help with sleep and because clonidine sometimes helps moderate impulsive and oppositional behavior and may reduce tics. It may be more useful for comorbid Tourette syndrome.

Other

Some medications used to treat ADHD are prescribed off-label, outside the scope of their US government approved indications for various reasons. The U.S. FDA requires two clinical trials to prove a potential drug's safety and efficacy in treating ADHD. The drugs below have not been through these tests, so the efficacy is unproven (however these drugs have been licensed for other indications, so have been proven to be safe in those populations) and proper dosage and usage instructions are not as well characterized.

; Bupropion : Bupropion is classified as an atypical antidepressant. It is the most common off-label prescription for ADHD. It inhibits the reuptake of norepinephrine, and to a lesser extent dopamine, in neuronal synapses, and has little or no effect on serotonergic reuptake. Bupropion is not a controlled substance. It is commonly prescribed as a timed release formulation to decrease the risk of side effects. ; Modafinil : A wakefulness-promoting agent that operates primarily as a selective, relatively weak, and atypical dopamine reuptake inhibitor. Double-blind randomized controlled trials have demonstrated the efficacy and tolerability of modafinil in pediatric ADHD. There are risks of serious side effects such as skin reactions, however these are rare and modafinil is not recommended for use in children. In the United States, it was originally pending marketing on-label as Sparlon, but approval was denied by the FDA due to major concerns over the occurrence of Stevens–Johnson syndrome in clinical trials. ;Selegiline : Selegiline acts as a monoamine oxidase inhibitor, and increases levels of monoamine neurotransmitters in the brain. At doses under 20 mg/day, selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B), increasing levels of dopamine in the brain. In clinical trials, Selegiline has been used in the treatment of attention deficit hyperactivity disorder (ADHD). Selegiline may target specific symptoms of ADHD including: sustained attention, the learning of novel information, hyperactivity, and peer interactions. Selegiline has shown to be relatively effective in treating the inattention subtype of ADHD.

Other medications which may be prescribed off-label include certain antidepressants such as tricyclic antidepressants (TCAs), SNRIs, SSRIs, or MAOIs.

Antipsychotic medication

Atypical antipsychotic medications, which are approved for the treatment of certain behavioral disorders, are sometimes prescribed off-label as a combination therapy with stimulants for the treatment of comorbid (i.e., co-occurring diseases) ADHD and disruptive behavioral disorders. Canadian clinical practice guidelines only support the use of dopaminergic antipsychotics with selectivity for D2-type dopamine receptors, particularly risperidone, as a third-line treatment for both disorders following the failure of stimulant monotherapy and psychosocial interventions. Combined use of D2-type receptor antagonists and ADHD stimulants for the treatment of ADHD with comorbid behavioral disorders does not appear to have significantly worse adverse effects than ADHD stimulant or antipsychotic monotherapy. Research suggests, but has not yet confirmed, the treatment efficacy of antipsychotic and stimulant combination treatment for both disorders;

Dopaminergic antipsychotics affect dopamine neurons by binding to postsynaptic dopamine receptors, where they function as receptor antagonists. In contrast, ADHD stimulants are indirect agonists of postsynaptic dopamine receptors; in other words, these stimulants increase levels of synaptic dopamine, which then binds to postsynaptic receptors. Stimulants increase the concentration of synaptic dopamine by activating certain presynaptic receptors (i.e., TAAR1) or by blocking or altering the function of reuptake transporters (e.g., DAT, VMAT2) in the presynaptic neuron.

Comparison

Concerns regarding stimulants

Main article: Attention-deficit hyperactivity disorder controversies#Concerns about medication

Some parents and professionals have raised questions about the side effects of drugs and their long-term use.

Increasing use

Outpatient treatment rates held steady in the U.S. from the late 1990s to early 2000s. Prior to this, outpatient treatment for ADHD in the U.S. grew from 0.9 children per 100 in 1987 to 3.4 per 100 in 1997. A survey conducted by the Centers for Disease Control and Prevention in 2011–2012 found 11% of children between the ages of 4 and 17 were reported to have ever received a health care provider diagnosis of ADHD at some point (15% of boys and 7% of girls), a 16% increase since 2007 and a 41% increase over the last decade. The CDC notes that community samples suggest the incidence of ADHD in American children is higher than the five percent stated by the American Psychiatric Association in DSM-5, with 8.8% of U.S. children having a current diagnosis in the 2011 survey. However, only 6.1% of children in the 2011 survey were taking ADHD medication, suggesting as many as 17.5% of children with current ADHD were not receiving treatment.

Use in preschoolers

Parents of children with ADHD note that they usually display their symptoms at an early age. There have been few longitudinal studies on the long-term effects of stimulant use in children. The use of stimulant medication has not been approved by the FDA for children under the age of six. A growing trend is the diagnosis of younger children with ADHD. Prescriptions for children under the age of 5 rose nearly 50 percent from 2000 to 2003. Research on this issue has indicated that stimulant medication can help younger children with "severe ADHD symptoms" but typically at a lower dose than older children. It was also found that children at this age are more sensitive to side effects and should be closely monitored. Evidence suggests that careful assessment and highly individualized behavioural interventions significantly improve both social and academic skills, while medication only treats the symptoms of the disorder. "One of the primary reasons cited for the growing use of psychotropic interventions was that many physicians realize that psychological interventions are costly and difficult to sustain."

Side effects

Gastrointestinal

At therapeutic doses, amphetamine and methylphenidate may cause decreased appetite and abdominal pain, as well as constipation, indigestion, and nausea. Non-stimulant medications can also produce gastrointestinal side effects; atomoxetine has been associated with nausea and abdominal discomfort, while the alpha-2 adrenoreceptor agonists guanfacine and clonidine may cause constipation and abdominal pain.

Growth delay and weight loss

There is some evidence of mild reductions in growth rate with prolonged stimulant treatment in children, but no causal relationship has been established and reductions do not appear to persist long-term. Weight loss almost always corresponds with loss of appetite, which may result from the medication. Severe weight loss is very uncommon though. Loss of appetite is very temporary and typically comes back as daily effects of stimulants wear off. Nausea, dizziness, and headaches, other side effect, can also indirectly affect appetite and result in weight loss.

Cardiovascular

There is concern that stimulants and atomoxetine, which increase the heart rate and blood pressure, might cause serious cardiovascular problems. Recent extremely large-scale studies by the FDA indicate that, in children, young adults, and adults, there is no association between serious adverse cardiovascular events (sudden death, myocardial infarction, and stroke) and the medical use of amphetamine, methylphenidate, or other ADHD stimulants.

Psychiatric

Many of these drugs are associated with physical and psychological dependence. Sleep problems may occur.

Methylphenidate can worsen psychosis in psychotic patients, and in very rare cases it has been associated with the emergence of new psychotic symptoms. It should be used with extreme caution in patients with bipolar disorder due to the potential induction of mania or hypomania. There have been very rare reports of suicidal ideation, but evidence does not support a link. The long-term effects on mental health disorders in later life of chronic use of methylphenidate is unknown.

A 2009 FDA review of 49 clinical trials found that approximately 1.5% of children in clinical trials of medications for ADHD had experienced signs or symptoms of psychosis or mania. Postmarketing reports were also analyzed, with nearly half of them involving children under the age of eleven. Approximately 90% of cases had no reported previous history of similar psychiatric events. Hallucinations involving snakes, worms or insects were the most commonly reported symptoms.

Long-term use

Long-term methylphenidate or amphetamine exposure in some species is known to produce abnormal dopamine system development or nerve damage, but humans experience normal development and nerve growth. Magnetic resonance imaging studies suggest that long-term treatment with amphetamine or methylphenidate decreases abnormalities in brain structure and function found in subjects with ADHD, and improves function of the right caudate nucleus.

Reviews of clinical stimulant research have established the safety and effectiveness of long-term amphetamine use for ADHD. Controlled trials spanning two years have demonstrated continuous treatment effectiveness and safety. One review highlighted a nine-month randomized controlled trial of amphetamine in children that found an average increase of 4.5 IQ points and continued improvements in attention, disruptive behaviors, and hyperactivity.

There is some evidence that ADHD itself may protect the brain against the natural aging process later in life, perhaps by exercising the brain, and helping maintain volume. It is unknown how long term medication treatment effects the trajectory of brain volume decline in the aging ADHD brain.

Withdrawal and rebound

Tolerance to the therapeutic effects of stimulants can occur, and rebound of symptoms may occur when the dose wears off. Rebound effects are often the result of the stimulant dosage being too high or the individual not being able to tolerate stimulant medication. Signs that the stimulant dose is too high include irritability, feeling stimulated or blunting of affect and personality.

Stimulant withdrawal or rebound reactions can occur and can be minimised in intensity via a gradual tapering off of medication over a period of weeks or months. A small study of abrupt withdrawal of stimulants did suggest that withdrawal reactions are not typical, and may only occur in susceptible individuals.

Cancer

Concerns about chromosomal aberrations and possible cancer later in life was raised by a small-scale study on the use of methylphenidate, though a review by the Food and Drug Administration (FDA) found significant methodological problems with the study. A follow-up study performed with improved methodology found no evidence that methylphenidate might cause cancer, stating "the concern regarding a potential increase in the risk of developing cancer later in life after long-term MPH treatment is not supported."

History

The first reported evidence of stimulant medication used to treat children with concentration and hyperactivity problems came in 1937. Charles Bradley in Providence, Rhode Island, reported that a group of children with behavioral problems improved after being treated with the stimulant Benzedrine. In 1954, the stimulant methylphenidate (Ritalin, which was first produced in 1944) became available; it remains one of the most widely prescribed medications for ADHD. Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ADHD in the 1960s and steadily rose in use.

In 1975, pemoline (Cylert) was approved by the U.S. FDA for use in the treatment of ADHD. While an effective agent for managing the symptoms, the development of liver failure in 14 cases over the next 27 years would result in the manufacturer withdrawing this medication from the market. New delivery systems for medications were invented in 1999 that eliminated the need for multiple doses across the day or taking medication at school. These new systems include pellets of medication coated with various time-release substances to permit medications to dissolve hourly across an 8–12 hour period (Metadate CD, Adderall XR, Focalin XR) and an osmotic pump that extrudes a liquid methylphenidate sludge across an 8–12 hour period after ingestion (Concerta).

In 2003, atomoxetine (Strattera) received the first FDA approval for a nonstimulant drug to be used specifically for ADHD. In 2007, lisdexamfetamine (Vyvanse) became the first prodrug for ADHD to receive FDA approval. In March 2019, a Purdue Pharma subsidiary received approval from the FDA for Adhansia XR, a methylphenidate medication to treat ADHD.

Cost-effectiveness

Combined medical management and behavioral treatment is the most effective ADHD management strategy, followed by medication alone, and then behavioral treatment. In terms of cost-effectiveness, management with medication has been shown to be the most cost-effective, followed by behavioral treatment, and combined treatment. The individually most effective and cost-efficient way is with stimulant medication. Additionally, long-acting medications for ADHD, in comparison to short-acting varieties, generally seem to be cost-effective. Comorbid (relating to two diseases that occur together, e.g. depression and ADHD) disorders makes finding the right treatment and diagnosis much more costly than when comorbid disorders are absent.

Alternative medicine

Most alternative therapies do not have enough supporting evidence to recommend them. Moreover, when only the best conducted studies are taken into account results tend to be similar to placebo.

Behavioral Therapy

According to a study done by the National Institute of Mental Health, medication, either alone or combined with behavioral therapy was the most effective course of treatment in reducing ADHD symptoms. They also found that although medication had some long-term side effects, it was ultimately safer and more effective than routine community care. The researchers studies 600 7-9 year old children and found that the benefits lasted at least 14 months with great improvement in academic performance and social skills. The researchers also found that combining medication with behavioral therapy allowed for the same effectiveness with a lower dosage of medicine.

Neurofeedback

Neurofeedback (NF) or EEG biofeedback is a treatment strategy used for children, adolescents and adults with ADHD. The human brain emits electrical energy which is measured with electrodes. Neurofeedback alerts the patient when beta waves are present. This theory believes that those with ADHD can train themselves to decrease ADHD symptoms.

No serious adverse side effects from neurofeedback have been reported. Research into neurofeedback has been mostly limited and of low quality. While there is some indication on the effectiveness of biofeedback it is not conclusive: several studies have yielded positive results, however the best designed ones have either shown reduced effects or non-existing ones. In general no effects have been found in the most blinded ADHD measures, which could be indicating that positive results are due to the placebo effect.

Media

Preliminary studies have supported the idea that playing video games is a form of neurofeedback, which helps those with ADHD self-regulate and improve learning. Memory, multitasking, fluid intelligence, and other cognitive talents may be improved by certain computer programmes and video games. On the other hand, ADHD may experience great difficulty disengaging from the game, which may in turn negate any benefits gained from these activities, and time management skills may be negatively impacted as well.

Nature

Children who spend time outdoors in natural settings, such as parks, seem to display fewer symptoms of ADHD, which has been dubbed "Green Therapy". Nature-based interventions may serve as useful adjuncts to pharmacological or behavioral therapy treatments for ADHD, particularly in cases where medications are less preferred or recommended. Such interventions are touted for their general health benefits and high safety profile, despite the need for more robust randomized control trials to examine their efficacy as a treatment modality for ADHD.

Diet

Main article: Diet and attention deficit hyperactivity disorder

There is insufficient evidence to support dietary changes in ADHD and thus they are not recommended by the American Academy of Pediatrics as of 2019. Perhaps the best known of the dietary alternatives is the Feingold diet which involves removing salicylates, artificial colors and flavors, and certain synthetic preservatives from children's diets. However, studies have shown little if any effect of the Feingold diet on the behavior of children with ADHD.

Results of studies regarding the effect of eliminating artificial food coloring from the diet of children with ADHD have been very varied. It has been found that it might be effective in some children but as the published studies have been of low quality results can be more related to research problems such as publication bias. The UK Food Standards Agency (FSA) has called for a ban on the use of six artificial food colorings and the European Union (EU) has ruled that some food dyes must be labeled with the relevant E number as well as this warning: "may have an adverse effect on activity and attention in children." Nevertheless, existing evidence neither refutes nor supports the association between ADHD and food colouring.

Dietary supplements, self-medication, and specialized diets are sometimes used by people with ADHD with the intent to mitigate some or all of the symptoms. However a 2009 article in the Harvard Mental Health Letter states, "Although vitamin or mineral supplements [micronutrients] may help children diagnosed with particular deficiencies, there is no evidence that they are helpful for all children with ADHD. Furthermore, megadoses of vitamins, which can be toxic, must be avoided." In the United States, no dietary supplement has been approved for the treatment for ADHD by the FDA.

Some popular supplements used to manage ADHD symptoms:

• Caffeine – ADHD is associated with increased caffeine consumption, and caffeine's stimulant effects on cognition may have some benefits for ADHD. Limited evidence suggests a small therapeutic effect that is markedly inferior to standard treatments like methylphenidate and dextroamphetamine while still producing similar or greater side effects.
• Nicotine – The association between ADHD and nicotine intake is well known, and limited evidence suggests that nicotine may help improve some of the symptoms of ADHD, although the effect is generally small.
• Omega-3 fatty acids – There is no evidence that supplementation with omega-3 or other polyunsaturated fatty acids provides any improvement in the symptoms of ADHD in children or adolescents. A 2011 meta analysis found a "small but significant benefit", with benefits being "modest compared to the efficacy of currently available pharmacological treatments for ADHD". The review concluded that supplementation may be worth consideration as an augmentative treatment in combination with medication due to its "relatively benign side-effect profile", but not as a primary treatment. Most research on omega-3 fatty acids is considered to be of very poor quality with widespread methodological weaknesses.
• Zinc – Although the role of zinc in ADHD has not been elucidated, there is a small amount of limited evidence that lower tissue zinc levels may be associated with ADHD. In the absence of a demonstrated zinc deficiency (which is rare outside of developing countries), zinc supplementation is not recommended as a treatment option for ADHD.
• In the 1980s vitamin B6 was promoted as a helpful remedy for children with learning difficulties including inattentiveness; however, a study of large doses of vitamins with ADHD children showed that they were ineffective in changing behavior.

Exercise

Regular physical exercise, particularly aerobic exercise, is an effective add-on treatment for ADHD in children and adults, particularly when combined with stimulant medication (although the best intensity and type of aerobic exercise for improving symptoms are not currently known). The long-term effects of regular aerobic exercise in ADHD individuals include better behavior and motor abilities, improved executive functions (including attention, inhibitory control, and planning, among other cognitive domains), faster information processing speed, and better memory. Parent-teacher ratings of behavioral and socio-emotional outcomes in response to regular aerobic exercise include: better overall function, reduced ADHD symptoms, better self-esteem, reduced levels of anxiety and depression, fewer somatic complaints, better academic and classroom behavior, and improved social behavior. Exercising while on stimulant medication augments the effect of stimulant medication on executive function. It is believed that these short-term effects of exercise are mediated by an increased abundance of synaptic dopamine and norepinephrine in the brain.

Based on a 2024 systematic literature review and meta analysis commissioned by the Patient-Centered Outcomes Research Institute (PCORI), seven randomized control trials were identified that report on the effectiveness of physical exercise for treating ADHD symptoms. The type and amount of exercise varied widely across studies from martial arts interventions to treadmill training, to table tennis or aerobic exercise. Because any effects reported were not replicated, the authors concluded that there is currently insufficient evidence that exercise intervention is an effective form of treatment for ADHD symptoms for children and adolescents.

Comorbid disorders

Because ADHD comorbidities are diverse and the rate of comorbidity is high, special care must be dedicated to certain comorbidities. The FDA is not set up to address this issue, and does not approve medications for comorbidities, nonetheless certain such topics have been extensively researched.

Tic disorders

Patients with Tourette syndrome who are referred to specialty clinics have a high rate of comorbid ADHD. Patients who have ADHD along with tics or tic disorders may also have problems with disruptive behaviors, overall functioning, and cognitive function, accounted for by the comorbid ADHD.

The treatment of ADHD in the presence of tic disorders has long been a controversial topic. Past medical practice held that stimulants could not be used in the presence of tics, due to concern that their use might worsen tics; however, multiple lines of research have shown that stimulants can be cautiously used in the presence of tic disorders.

A 2011 Cochrane Collaboration review concluded that most major ADHD medications were effective in children with tics, and that stimulants did not generally worsen tics outside of individual cases. Methylphenidate, guanfacine, clonidine, and desipramine were associated with improvement of tic symptoms. Controversy remains, and the PDR continues to carry a warning that stimulants should not be used in the presence of tic disorders, so physicians may be reluctant to use them. Others are comfortable using them and even advocate for a stimulant trial when ADHD co-occurs with tics, because the symptoms of ADHD can be more impairing than tics.

The stimulants are the first line of treatment for ADHD, with proven efficacy, but they do fail in up to 20% of cases, even in patients without tic disorders. Current prescribed stimulant medications include: methylphenidate, dextroamphetamine, and mixed amphetamine salts (Adderall). Other medications can be used when stimulants are not an option. These include the alpha-2 agonists (clonidine and guanfacine), tricyclic antidepressants (desipramine and nortriptyline), and newer antidepressants (bupropion and venlafaxine). There have been case reports of tics worsening with bupropion. There is good empirical evidence for short-term safety and efficacy for the use of desipramine, bupropion and atomoxetine.

References

References

1. (2024-04-01). "Treatments for ADHD in Children and Adolescents: A Systematic Review". Pediatrics.
2. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics.
3. (2024-03-25). "ADHD Diagnosis and Treatment in Children and Adolescents". Agency for Healthcare Research and Quality (AHRQ).
4. Stein, Mark A.. (July 2004). "Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments". American Journal of Managed Care.
5. (August 2004). "Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder". Pharmacotherapy.
6. Hazell, P. (October 2005). "Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?". Expert Opinion on Pharmacotherapy.
7. (2024). "ADHD Diagnosis and Treatment in Children and Adolescents".
8. Waxmonsky, James. (October 2003). "Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness". Current Opinion in Pediatrics.
9. (2010). "Psychosocial Interventions to Improve the School Performance of Students with Attention-Deficit/Hyperactivity Disorder". Mind & Brain: The Journal of Psychiatry.
10. (2018). "A Descriptive Review of ADHD Coaching Research: Implications for College Students". Journal of Postsecondary Education and Disability.
11. (2024-03-25). "ADHD Diagnosis and Treatment in Children and Adolescents". Agency for Healthcare Research and Quality (AHRQ).
12. (21 June 2019). "Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years". The Cochrane Database of Systematic Reviews.
13. (October 2001). "Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder". Pediatrics.
14. Kazdin, Alan E. Parent management training: treatment for oppositional, aggressive, and antisocial behavior in children and adolescents. Oxford University Press, 2005
15. (2019-10-01). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics.
16. "Guidelines for better facilitation in school for students with ADHD".
17. (February 2013). "Is working memory training effective? A meta-analytic review". Dev Psychol.
18. (October 2014). "Computer-based Cognitive Training for ADHD: A Review of Current Evidence". Child and Adolescent Psychiatric Clinics of North America.
19. (April 2023). "Computerized cognitive training in attention-deficit/hyperactivity disorder (ADHD): a meta-analysis of randomized controlled trials with blinded and objective outcomes". Molecular Psychiatry.
20. (April 2005). "Mechanisms of neurotransmitter release by amphetamines: a review". Progress in Neurobiology.
21. Howland RH. (August 2008). "Lisdexamfetamine: a prodrug stimulant for ADHD". Journal of Psychosocial Nursing and Mental Health Services.
22. (September 2017). "Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment". The Journal of Pharmacology and Experimental Therapeutics.
23. National Toxicology Program. (July 2005). "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines". NTP Cerhr Mon.
24. "ADHD Medications: How They Work & Side Effects".
25. (2022-02-01). "Evidence-based pharmacological treatment options for ADHD in children and adolescents". Pharmacology & Therapeutics.
26. (2006-10-05). "Comparing the Efficacy of Medications for ADHD Using Meta-analysis". Medscape General Medicine.
27. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
28. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
29. (June 2015). "The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex". Biological Psychiatry.
30. (October 2014). "Effects of Stimulants on Brain Function in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis". Biological Psychiatry.
31. Wilens, Timothy E.. (June 2008). "Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder". Journal of Clinical Psychopharmacology.
32. (July 2006). "A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents". Health Technology Assessment.
33. (2005). "Attention-Deficit Hyperactivity Disorder: A Clinical Workbook". Guilford Press.
34. (September 2002). "When children with attention-deficit/hyperactivity disorder become adults". South. Med. J..
35. (January 2008). "Long-term safety of stimulant medications used to treat children with ADHD". Pediatric Annals.
36. (15 July 2014). "Full U.S. Concerta Prescribing Information". Janssen Pharmaceuticals, Inc..
37. Advokat, Claire. (2010-07-01). "What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD)". Neuroscience & Biobehavioral Reviews.
38. (2005). "Cost-Effectiveness of ADHD Treatments: Findings from the Multimodal Treatment Study of Children With ADHD". American Journal of Psychiatry.
39. (2006). "Effectiveness outcomes in attention-deficit/hyperactivity disorder". J Clin Psychiatry.
40. (2018). "Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis". Neuroscience & Biobehavioral Reviews.
41. (1 August 2015). "Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study". The Lancet. Psychiatry.
42. Arnold, LE. (2000). "Methylphenidate vs Amphetamine: Comparative Review". Journal of Attention Disorders.
43. (2002). "Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002". J Atten Disord.
44. (February 2008). "Treatment of adults with attention-deficit/hyperactivity disorder". Neuropsychiatr Dis Treat.
45. Spencer TJ. (April 2007). "Pharmacology of adult ADHD with stimulants". CNS Spectr.
46. Rostain, Anthony L.. (September 2008). "ADHD in Adults: Attention-Deficit/Hyperactivity Disorder in Adults: Evidence-Based Recommendations for Management". Postgraduate Medicine.
47. Spencer, Thomas. (June 2004). "Stimulant treatment of adult attention-deficit/hyperactivity disorder". Psychiatric Clinics of North America.
48. (2025). "Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis". The Lancet. Psychiatry.
49. Higgins ES. (January 1999). "A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder". J Fam Pract.
50. (February 2009). "Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review". Adv Ther.
51. (June 2013). "Amphetamine, past and present – a pharmacological and clinical perspective". J. Psychopharmacol..
52. "National Drug Code Amphetamine Search Results". United States Food and Drug Administration.
53. (June 2017). "Mydayis Prescribing Information". Shire US Inc..
54. (January 2017). "Adzenys XR-ODT Prescribing Information". Neos Therapeutics, Inc..
55. "Adzenys XR-ODT".
56. (May 2017). "Dyanavel XR Prescribing Information". Tris Pharma, Inc..
57. (May 2025). "Dyanavel XR".
58. "Evekeo".
59. (January 2017). "Vyvanse Prescribing Information". Shire US Inc..
60. (May 2025). "Xelstrym (dextroamphetamine) transdermal system, CII: Highlights of Prescribing Information". United States Food and Drug Administration}}{{dead link.
61. (2022). "Goodman & Gilman's Pharmacological Basis of Therapeutics". McGraw-Hill.
62. (October 2012). "A practical guide to the therapy of narcolepsy and hypersomnia syndromes". Neurotherapeutics.
63. Punja, Salima. (February 2016). "Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents". Cochrane Database of Systematic Reviews.
64. (2015). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
65. (February 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". Annals of Pharmacotherapy.
66. (October 2002). "Comparative Efficacy of Adderall and Methylphenidate in Attention-deficit/Hyperactivity Disorder: A Meta-Analysis". Journal of Clinical Psychopharmacology.
67. (April 2010). "Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis". European Child & Adolescent Psychiatry.
68. (2025-03-20). "The effects of psychostimulants in menstruating women with ADHD - A gender health gap in ADHD treatment?". Progress in Neuro-Psychopharmacology & Biological Psychiatry.
69. (2025). "A Review of Sex and Gender Factors in Stimulant Treatment for ADHD: Knowledge Gaps and Future Directions". Journal of Attention Disorders.
70. (2020). "The female side of pharmacotherapy for ADHD-A systematic literature review". PLOS ONE.
71. (2025-06-03). "Medical management of ADHD in adults: part 2". Drug and Therapeutics Bulletin.
72. (2015). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
73. (2003). "Methamphetamine and Amphetamine Pharmacokinetics in Oral Fluid and Plasma after Controlled Oral Methamphetamine Administration to Human Volunteers". Clinical Chemistry.
74. Shoblock. (2003). "Neurochemical and Behavioral Differences Between D-Methamphetamine and D-Amphetamine in Rats". Psychopharmacology.
75. "Education/Training » Clinical Resources". University of Illinois at Chicago.
76. (31 March 2005}}{{Update inline). "Apo‑Methylphenidate SR product monograph". Apotex Inc..
77. (5 May 2009). "New product: Sandoz Methylphenidate SR 20 mg". Sandoz Canada Inc..
78. "Drugs@FDA: FDA Approved Drug Products". US Food and Drug Administration.
79. (15 July 2014). "Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder". American Journal of Health-System Pharmacy.
80. (November 2009). "A review of long-acting medications for ADHD in Canada". Journal of the Canadian Academy of Child and Adolescent Psychiatry.
81. "Aptensio XR Prescribing Information".
82. Moses, Scott. (26 July 2009). "Methylphenidate". Family Practice Notebook.
83. "Daytrana transdermal". WebMD.
84. "QUILLICHEW ER™ (Methylphenidate HCl extended-release chewable tablets CII) {{!}} Pfizer Medical Information – US". Pfizer.
85. "AZSTARYS® (serdexmethylphenidate and dexmethylphenidate)".
86. (June 2008). "Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?". Journal of Clinical Psychopharmacology.
87. (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". CNS Drugs.
88. (May 2016). "A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients". Journal of Psychopharmacology.
89. (November 2011). "Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate: A Direct Comparison Meta-Analysis". Journal of Attention Disorders.
90. (December 2011). "Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis". BMC Psychiatry.
91. (10 February 2016). "Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis". Medical Journal of the Islamic Republic of Iran.
92. "Atomoxetine (marketed as Strattera) Information".
93. (March 2024). "ADHD Diagnosis and Treatment in Children and Adolescents". National Library of Medicine.
94. "Atomoxetine: MedlinePlus Drug Information".
95. (22 February 2007). "Atomoxetine (marketed as Strattera) Information". FDA Center for Drug Evaluation and Research.
96. (February 2014). "Strattera Prescribing Information". Eli Lilly and Company.
97. (December 2005). "Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders". Neurology.
98. "Qelbree: FDA-Approved Drugs".
99. (2 April 2021). "Supernus Announces FDA Approval of Qelbree (SPN-812) for the Treatment of ADHD".
100. Arnsten AF. (2010). "The use of alpha-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder". Expert Rev Neurother.
101. Frazin, Natalie. (2 April 2002). "Methylphenidate and Clonidine Help Children With ADHD and Tics". [[National Institute of Neurological Disorders and Stroke]].
102. (March 2005). "C-10. Educational course: ADHD through the life span". European Psychiatry.
103. "Wellbutrin: Prescribing Information".
104. (2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor". Prim Care Companion J Clin Psychiatry.
105. (2017-10-02). "Bupropion for attention deficit hyperactivity disorder (ADHD) in adults". Cochrane Database of Systematic Reviews.
106. (May 2006). "A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study". The Journal of Clinical Psychiatry.
107. (May 2006). "A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder". Journal of the American Academy of Child and Adolescent Psychiatry.
108. Cephalon, Inc.. (21 December 2007). "Modavigil Product Information". healthlinks.net Pty. Ltd..
109. (January 2020). "StatPearls". StatPearls Publishing.
110. (2006). "Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder". Journal of Child and Adolescent Psychopharmacology.
111. (May 2013). "Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability". Current Psychiatry Reports.
112. (9 August 2017). "Atypical antipsychotics for disruptive behaviour disorders in children and youths". The Cochrane Database of Systematic Reviews.
113. (February 2015). "Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder". Canadian Journal of Psychiatry.
114. (2010). "Goodman and Gilman's The Pharmacological Basis of Therapeutics". McGraw-Hill Professional.
115. (2005). "Attention Deficit Hyperactivity Disorder". Humana Press.
116. (February 2012). "Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents". Drugs.
117. (September 2011). "Efficacy and Tolerability of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder in Adults". CNS Drugs.
118. (June 2010). "A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes". Journal of Clinical Psychiatry.
119. (April 2014). "Evekeo Prescribing Information". Arbor Pharmaceuticals LLC.
120. (June 2001). "Efficacy of Adderall and Methylphenidate in Attention Deficit Hyperactivity Disorder: A Reanalysis Using Drug–Placebo and Drug–Drug Response Curve Methodology". Journal of Child and Adolescent Psychopharmacology.
121. "amphetamine/dextroamphetamine (Rx) – Adderall XR, Adderall".
122. (December 2009). "Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths". Pharmacy and Therapeutics.
123. (October 2006). "Comparing the Efficacy of Medications for ADHD Using Meta-analysis". MedGenMed.
124. "lisdexamfetamine (Rx) – Vyvanse".
125. "methamphetamine (Rx) – Desoxyn".
126. "methylphenidate (Rx) – Ritalin, Ritalin SR".
127. "dexmethylphenidate (Rx) – Focalin, Focalin XR".
128. "atomoxetine (Rx) – Strattera".
129. "modafinil (Rx) – Provigil".
130. (2008). "Approved and investigational uses of modafinil: an evidence-based review". Drugs.
131. "clonidine (Rx) – Catapres, Catapres-TTS".
132. (2013). "Australian Medicines Handbook". The Australian Medicines Handbook Unit Trust.
133. "guanfacine (Rx) – Intuniv, Tenex".
134. "amitriptyline (Rx) – Elavil, Levate".
135. (September 1999). "[Use of amitriptyline in attention deficit hyperactivity disorder]". Arq Neuropsiquiatr.
136. "bupropion (Rx) – Wellbutrin, Zyban".
137. (December 2011). "Bupropion for adults with attention-deficit hyperactivity disorder: Meta-analysis of randomized, placebo-controlled trials". Psychiatry and Clinical Neurosciences.
138. (2015-06-01). "Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis with focus on bupropion". Journal of Affective Disorders.
139. "buspirone (Rx) – BuSpar, Buspirex".
140. (April 1998). "An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder". Journal of the American Academy of Child and Adolescent Psychiatry.
141. (November 2012). "Buspirone versus Methylphenidate in the Treatment of Children with Attention- Deficit/ Hyperactivity Disorder: Randomized Double-Blind Study". Acta Medica Iranica.
142. (2012). "An 8-Week, Randomized Controlled Trial of Atomoxetine, Atomoxetine Plus Buspirone, or Placebo in Adults With ADHD". The Journal of Clinical Psychiatry.
143. (2010). "Buspirone Versus Methylphenidate in the Treatment of Attention Deficit Hyperactivity Disorder: A Double-Blind and Randomized Trial". Child Psychiatry and Human Development.
144. (November 2010). "Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors". The International Journal of Neuropsychopharmacology.
145. (November 2005). "Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action". The Journal of Neuroscience.
146. (July 1983). "Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children". Journal of the American Academy of Child Psychiatry.
147. "desipramine (Rx) – Norpramin".
148. (19 September 2014). "Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents". The Cochrane Database of Systematic Reviews.
149. "duloxetine (Rx) – Cymbalta".
150. (May 2012). "Duloxetine in Adults With ADHD: A Randomized, Placebo-Controlled Pilot Study". Journal of Attention Disorders.
151. "imipramine (Rx) – Tofranil, Tofranil-PM".
152. (November 1999). "Attention-Deficit/Hyperactivity Disorder (ADHD) as a Noradrenergic Disorder". Biological Psychiatry.
153. "milnacipran (Rx) – Savella".
154. (April 2007). "A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran". Progress in Neuro-Psychopharmacology and Biological Psychiatry.
155. (April 1995). "Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders". Acta Psychiatrica Scandinavica.
156. "nortriptyline (Rx) – Pamelor, Aventyl".
157. (March 1993). "Nortriptyline in the treatment of ADHD: a chart review of 58 cases". Journal of the American Academy of Child and Adolescent Psychiatry.
158. (January 1993). "Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome". Journal of the American Academy of Child and Adolescent Psychiatry.
159. (May 2015). "A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder". Nordic Journal of Psychiatry.
160. (August 2006). "Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder". Journal of Child and Adolescent Psychopharmacology.
161. "venlafaxine (Rx) – Effexor, Effexor XR".
162. (March 2013). "Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials". [[Reviews on Recent Clinical Trials]].
163. "amantadine (Rx) – Endantadine, Symmetrel".
164. (2010). "Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial". Human Psychopharmacology.
165. "carbamazepine (Rx) – Tegretol, Equetro".
166. (March 1996). "Carbamazepine Use in Children and Adolescents with Features of Attention-Deficit Hyperactivity Disorder: A Meta-Analysis". Journal of the American Academy of Child and Adolescent Psychiatry.
167. (July 2000). "Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder". Child and Adolescent Psychiatric Clinics of North America.
168. "memantine (Rx) – Namenda XR".
169. (May 2013). "A pilot open label prospective study of memantine monotherapy in adults with ADHD". The World Journal of Biological Psychiatry.
170. (20 October 2007). "The impact of prescribed psychotropics on youth". Clinical Practice and Epidemiology in Mental Health.
171. (2003). "National trends in the treatment of attention deficit hyperactivity disorder". American Journal of Psychiatry.
172. (2018-03-04). "Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016". Journal of Clinical Child & Adolescent Psychology.
173. (January 2014). "Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011". Journal of the American Academy of Child and Adolescent Psychiatry.
174. (13 November 2013). "Attention-Deficit / Hyperactivity Disorder: Data & Statistics". Centers for Disease Control and Prevention.
175. (2008). "Beyond polemics: science and ethics of ADHD". Nature Reviews Neuroscience.
176. (November 2006). "Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD". J Am Acad Child Adolesc Psychiatry.
177. Freudenheim, Milt. (17 May 2004). "Behavior Drugs Lead in Sales For Children". The New York Times.
178. (24 October 2006). "Medco Settles Fraud, Kickback Charges for $155 Million". Consumers Unified LLC.
179. (November 2011). "ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents". Pediatrics.
180. (2006). "Treating Severe ADHD in Very Young Children". Medscape Psychiatry.
181. (2017-06-15). "Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials". PLOS ONE.
182. (2016-05-10). "Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review". JAMA.
183. (March 2013). "Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents". Journal of Child Psychology and Psychiatry, and Allied Disciplines.
184. "Tips to Ease ADHD Drug Side Effects in Adults".
185. Gelperin, Kate. (9 February 2006). "Studying Cardiovascular Risk with Drug Treatments of ADHD: Feasibility of Available Study Methods in Children and Adults". Food and Drug Administration (US)}}{{dead link.
186. (March 2017). "Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine". CNS Drugs.
187. (November 2011). "ADHD drugs and serious cardiovascular events in children and young adults". N. Engl. J. Med..
188. (15 December 2011). "FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults". United States Food and Drug Administration.
189. (December 2011). "ADHD medications and risk of serious cardiovascular events in young and middle-aged adults". JAMA.
190. (20 December 2011). "FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults". United States Food and Drug Administration.
191. (2006). "ADHD Drug Labels". Food and Drug Administration (US).
192. (February 2006). "ADHD Medications: Say No to Side Effects". New Hope Media LLC.
193. (July 2010). "Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature". Clin Neuropharmacol.
194. (2008). "Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients". Psychopharmacology Bulletin.
195. (December 1999). "Pharmacokinetics and clinical effectiveness of methylphenidate". Clin Pharmacokinet.
196. (1 February 2009). "Hallucinations and Other Psychotic Symptoms Associated With the Use of Attention-Deficit/Hyperactivity Disorder Drugs in Children". Pediatrics.
197. (August 2012). "Toxicity of amphetamines: an update". Arch. Toxicol..
198. (2008). "Abuse of amphetamines and structural abnormalities in the brain". Ann. N. Y. Acad. Sci..
199. (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". JAMA Psychiatry.
200. (September 2013). "Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies". J. Clin. Psychiatry.
201. (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects". Acta Psychiatrica Scandinavica.
202. Millichap JG. (2010). "Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD". Springer.
203. (July 2011). "Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge". CNS Drugs.
204. Millichap JG. (2010). "Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD". Springer.
205. (2022). "Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan". Front Hum Neurosci.
206. (March 2012). "Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis". Am J Psychiatry.
207. (2010). "European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD". BMC Psychiatry.
208. (October 2008). "ADD/ADHD and Impaired Executive Function in Clinical Practice". Curr Psychiatry Rep.
209. Garland EJ. (1998). "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats". J. Psychopharmacol. (Oxford).
210. (April 1999). "Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder". Pediatrics.
211. Ackerman, Todd. (1 July 2005). "Closer look for possible Ritalin, cancer link". Houston Chronicle.
212. Walitza, Susanne. (June 2007). "Does Methylphenidate Cause a Cytogenetic Effect in Children with Attention Deficit Hyperactivity Disorder?". Environmental Health Perspectives.
213. (December 2010). "The history of attention deficit hyperactivity disorder". Atten Defic Hyperact Disord.
214. (July 1998). "Charles Bradley, M.D., 1902–1979". American Journal of Psychiatry.
215. "Straterra". FDA.
216. "Vyvance Approval". FDA.
217. (September 2007). "Vyvance". FDA.
218. (April 7, 2019). "Sacklers quit Purdue Pharma board amid shifts for OxyContin maker". [[Stamford Advocate]].
219. Schlander. (2007). "Long-acting medications for the hyperkinetic disorders: a note on cost-effectiveness". European Child & Adolescent Psychiatry.
220. Schlander, Michael. (2007). "Health Technology Assessments by the National Institute for Health and Clinical Excellence: A Qualitative Study". Springer.
221. (December 2012). "Complementary and alternative therapies for children and adolescents with ADHD.". Current Opinion in Pediatrics.
222. (1 March 2013). "Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments". The American Journal of Psychiatry.
223. Newcorn, Jeffrey H.. (2000). "The multimodal treatment study of children with attention deficit hyperactivity disorder". Current Psychiatry Reports.
224. (February 2007). "Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult". Disease-a-Month.
225. (July 2012). "Evidence-based information on the clinical use of neurofeedback for ADHD". Neurotherapeutics.
226. (October 2012). "Current status of neurofeedback for attention-deficit/hyperactivity disorder". Curr Psychiatry Rep.
227. (October 2014). "Neurofeedback for ADHD: A Review of Current Evidence". Child and Adolescent Psychiatric Clinics of North America.
228. (9 March 2006). "ADHD patients play video games as part of treatment". USA Today.
229. Butnik S.M.. (2005). "Neurofeedback in adolescents and adults with attention deficit hyperactivity disorder". Journal of Clinical Psychology.
230. (June 2020). "Brain health consequences of digital technology use". Dialogues in Clinical Neuroscience.
231. (2000). "Inhibition, ADHD, and computer games: The inhibitory performance of children and ADHD on computerized tasks and games". Journal of Attention Disorders.
232. Tolchinsky A.. (2011). "Problematic video game play in a college sample and its relationship to time management skills and Attention-Deficit/Hyperactivity disorder symptomology". Cyberpsychology, Behavior, and Social Networking.
233. (2005). "Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder". Mental Retardation and Developmental Disabilities Research Reviews.
234. (June 2023). "Non-pharmacological interventions for attention-deficit hyperactivity disorder in children and adolescents". The Lancet Child & Adolescent Health.
235. (June 2023). "Non-pharmacological interventions for attention-deficit hyperactivity disorder in children and adolescents". The Lancet Child & Adolescent Health.
236. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics.
237. (March 2003). "Nutrition in the treatment of attention-deficit hyperactivity disorder: a neglected but important aspect". Applied Psychophysiology and Biofeedback.
238. (1996). "Hyperactivity: is candy causal?". Critical Reviews in Food Science and Nutrition.
239. (January 2012). "Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives". J Am Acad Child Adolesc Psychiatry.
240. (23 October 2014). "Food coloring ban in the UK but usage continues for USA". BioHealthBase BRC Team.
241. (9 July 2008). "Modernising the Rules on Food Additives and Labelling of Azo Dyes". Global Data Systems.
242. (June 2011). "A research model for investigating the effects of artificial food colorings on children with ADHD". Pediatrics.
243. (December 2001). "Attention deficit hyperactivity disorder (ADHD) and substance use disorders.". Current Psychiatry Reports.
244. {{cite Q. Q28251071. link
245. (21 September 2007). "FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides". Food and Drug Administration.
246. (September 2014). "Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder—was this a correct decision? A literature review". Journal of Psychopharmacology.
247. (1985). "Objectively measured hyperactivity—II. Caffeine and amphetamine effects". Journal of Clinical Pharmacology.
248. (September 2010). "Diversity and variability of the effects of nicotine on different cortical regions of the brain – therapeutic and toxicological implications". Central Nervous System Agents in Medicinal Chemistry.
249. (October 2008). "ADHD and smoking: from genes to brain to behavior". Annals of the New York Academy of Sciences.
250. (December 2014). "Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date". CNS Drugs.
251. (April 2023). "Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents". Cochrane Database Syst Rev.
252. (October 2011). "Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis". J Am Acad Child Adolesc Psychiatry.
253. (2005). "Zinc in attention-deficit/hyperactivity disorder". Journal of Child and Adolescent Psychopharmacology.
254. (October 2014). "Nutritional supplements for the treatment of ADHD". Child and Adolescent Psychiatric Clinics of North America.
255. (1984). "Effects of megavitamin therapy on children with attention deficit disorders". Pediatrics.
256. (February 2017). "Sweat it out? The effects of physical exercise on cognition and behavior in children and adults with ADHD: a systematic literature review". Journal of Neural Transmission.
257. (July 2014). "Exercise reduces the symptoms of attention-deficit/hyperactivity disorder and improves social behaviour, motor skills, strength and neuropsychological parameters". Acta Paediatrica.
258. (September 2013). "Protection from genetic diathesis in attention-deficit/hyperactivity disorder: possible complementary roles of exercise". Journal of the American Academy of Child and Adolescent Psychiatry.
259. Freeman, Roger D.. "Tourette's Syndrome: minimizing confusion".
260. Tourette's Syndrome Study Group. (February 2002). "Treatment of ADHD in children with tics: a randomized controlled trial". Neurology.
261. (26 June 2018). "Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders". The Cochrane Database of Systematic Reviews.
262. (November 2000). "Tourette disorder". Pediatrics in Review.
263. (April 2006). "Contemporary assessment and pharmacotherapy of Tourette syndrome". NeuroRx.